Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221526 · ClinicalTrials.gov registry record
SPO2 Validation Study - Philips Fast 2025
A clinical trial of Pulse Oximetry, sponsored by Philips Clinical & Medical Affairs Global.
- Recruiting
- Registry status
- 72
- Enrollment target
- 1
- Study location
NCT07221526: Recruiting study of Pulse Oximetry, sponsored by Philips Clinical & Medical Affairs Global.
NCT07221526 is a study of Pulse Oximetry that is actively recruiting participants, run by Philips Clinical & Medical Affairs Global. The registered enrollment target is 72 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221526, a study of Pulse Oximetry, is actively recruiting participants, sponsored by Philips Clinical & Medical Affairs Global.
- RECRUITING
- Registry status
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
Clinical investigation is to validate the SpO2 accuracy of the M1133AX5, M1133AX6, and AlarX4 (nasal ala application) SpO2 sensors under test with the Philips FAST Pulse Oximetry technology.
Primary Outcome
Accuracy expressed in Arms of SpO2 measurements obtained from the M1133AX5, M1133AX6, and AlarX4 (nasal ala placement) SpO2 sensors under test with the Philips Pulse Oximetry technology over the range of 70-100% SaO2 in comparison to SaO2 as ground truth.
Conditions Studied
Interventions
- DEVICE NO INTERVENTION
Study Locations (1)
Colorado
- Element Materials Technology - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-10-28 |
| Est. Completion | 2026-01-09 |
What NCT07221526 shows while recruiting
NCT07221526 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 72 participants, a relatively small participant target.
The record links to 1 condition, with Pulse Oximetry appearing as the primary indexed condition, and to 1 intervention - of which NO INTERVENTION is the first listed.
NCT07221526 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT07221526 about?
NCT07221526 is a clinical study titled "SPO2 Validation Study - Philips Fast 2025". Clinical investigation is to validate the SpO2 accuracy of the M1133AX5, M1133AX6, and AlarX4 (nasal ala application) SpO2 sensors under test with the Philips FAST Pulse Oximetry technology.
What is the current status of trial NCT07221526?
This trial is currently recruiting. The enrollment target is 72 participants. The study started on 2025-10-28. Estimated completion is 2026-01-09.
What conditions does trial NCT07221526 study?
This clinical trial studies the following conditions: Pulse Oximetry.
What interventions are being tested in trial NCT07221526?
The interventions under investigation include: NO INTERVENTION (DEVICE).
Who is sponsoring clinical trial NCT07221526?
This trial is sponsored by Philips Clinical & Medical Affairs Global, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221526 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulse Oximetry
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI